What is Ligand Pharmaceuticals's value added tax receivable net, current?

Ligand Pharmaceuticals (LGND) reported value added tax receivable net, current of $1.84M in Q1 2026.

How has Ligand Pharmaceuticals's value added tax receivable net, current changed year-over-year?

Ligand Pharmaceuticals's value added tax receivable net, current increased by 132.9% year-over-year, from -$5.59M to $1.84M.

Revenue$51.7M+14.1%

Operating income$17.4M+148%

Net income-$13.3M+68.6%

EPS (diluted)-$0.67+69.7%

Cash & equivalents$115.1M+140%

Total debt$5.1M+14.2%

Total equity$997.3M+25.4%

Total assets$1.5B+69.2%

Operating cash flow$48.7M+291%

CapEx$228.0K+6.5%

Free cash flow$48.5M+289%

Market cap$5.6B+96.7%

Gross margin91.9%—

Operating margin34.5%+23.0pp

Net margin55.9%+35.7pp

FCF margin44.8%+16.8pp

Return on equity17.1%+11.5pp

Debt / equity0×0.0×

Current ratio21.3×+16.0×

Reported directly by Ligand Pharmaceuticals in its filing.

Tagged under the XBRL concept lgnd:ValueAddedTaxReceivableNetCurrent.

The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

What is Ligand Pharmaceuticals's value added tax receivable net, current?: Ligand Pharmaceuticals (LGND) reported value added tax receivable net, current of $1.84M in Q1 2026.
How has Ligand Pharmaceuticals's value added tax receivable net, current changed year-over-year?: Ligand Pharmaceuticals's value added tax receivable net, current increased by 132.9% year-over-year, from -$5.59M to $1.84M.